BenevolentAI
a clinical stage enabled drug discovery company scientific validation commercial validation regulatory validation well funded with key value in points in the near and medium term enabled | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
3 of 29
Similar slides by BenevolentAI
See diffirences between slides (animation)
Investor Conference
November 2022
the benevolent platform is and commercially validated and has already delivered asset in phase assets in exploratory stage programmes a leading covid treatment that is now approved successful target collaboration with further validates our approach with a total of novel targets selected for portfolio well funded with key value in points in the near and medium term scientifically | BenevolentAI
Investor Presentation
October 2022
the benevolent platform is and commercially validated and has already delivered asset in phase assets in exploratory stage programmes a leading covid treatment that is now approved successful target collaboration with further validates our approach with a total of novel targets selected for portfolio well funded with key value in points in the near and medium term scientifically | BenevolentAI
Investor Day
September 2022
the benevolent platform is and commercially validated and has already delivered asset in phase assets in exploratory stage programmes a leading covid treatment that is now approved successful target collaboration with further validates our approach with a total of novel targets selected for portfolio well funded with key value in points in the near and medium term scientifically | BenevolentAI
Related slides by other companies
Alkermes
Investor Day
March 2021
value enhancement plan includes evaluation of strategic opportunities evaluation of strategic opportunities monetization of non core assets strategic collaboration for and other oncology assets operational financial elements of legacy drug monetization of royalty delivery drug manufacturing business revenue streams from third party products platforms intellectual property preclinical and clinical assets outside of strategic portfolio risk sharing product development structures | Alkermes
Other recent decks by BenevolentAI
See all presentations (11 decks)
Investor Presentation
September 2024
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights